journal article·2025-03

Membrane Fusion Strategy Boosts Immune Homeostasis, Mobilizing Macrophages to Eliminate Bacteria and Accelerate Skin Regeneration in Infected Burn Wound

Xingyou Wang, Xiaoqing Sun, Yating Zeng, Shuyao Liu, Qiangying Yi, Yao Wu

Advanced Functional Materials· Volume 35· Issue 10
Publisher page

Abstract

Abstract Immunotherapy holds promise as an alternative to antibiotics in treating burn infections. However, the inadequacy of immune response or excessive inflammation both hinder effective bacterial clearance through immunotherapy, therefore necessitating a comprehensive approach that not only enhances immunotherapy against bacteria but also maintains immune homeostasis and promotes skin regeneration. Here, a membrane fusion‐driven combination immunotherapy is reported that mobilizes macrophages to address abovementioned limitations. The core–shell structured membrane fusion‐liposomes (MFL‐Gal‐Mal/Cur) can fuse their functional phospholipid shells with macrophages and bacteria, resulting in the remodeling of targets' surfaces with the galactose‐maltotriose (Gal‐Mal) moieties, and delivering their cores (curcumin‐loaded mesoporous polydopamine, MPDA/Cur) into targets. The embedded Gal‐Mal on membranes enhances macrophages' ability to phagocytize bacteria, as well as increases bacteria's sensitivity to immune cell‐mediated killing. The intracellular MPDA/Cur evade lysosomal degradation, exerting antibacterial effects while also enhancing macrophage lysosomal bactericidal activity through autophagy promotion. This immunotherapy enhances macrophages’ capacity to phagocytize (increase rate for S. aureus: 21%; E. coli: 29%) and eliminate intracellular bacteria (clearance rate for S. aureus: 98%; E. coli: 99%), without exacerbating inflammatory responses. The release of MFL‐Gal‐Mal/Cur from the polysaccharide composite hydrogel can alleviate pain and itching sensations in infected burns, while activating the regeneration of skin appendages.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Wound Healing and Treatments · Advancements in Transdermal Drug Delivery · Extracellular vesicles in disease

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

National Engineering Research Center for Biomaterials Sichuan University Chengdu Sichuan 610064 P. R. China

Funding

National Key Research and Development Program of China · National Natural Science Foundation of China

References (50)

Show source-provided references
1. 10.1002/adfm.20230743910.1002/adfm.202307439 ↗
2. 10.1002/adma.20240136910.1002/adma.202401369 ↗
3. 10.1186/s12967-020-02248-510.1186/s12967-020-02248-5 ↗
4. 10.1002/adma.20230658910.1002/adma.202306589 ↗
5. 10.1016/S1473-3099(17)30753-310.1016/S1473-3099(17)30753-3 ↗
6. 10.1038/s41467-020-17670-y10.1038/s41467-020-17670-y ↗
7. 10.1042/ETLS2020034810.1042/ETLS20200348 ↗
8. 10.1126/science.aar671110.1126/science.aar6711 ↗
9. 10.1016/j.tim.2021.05.00510.1016/j.tim.2021.05.005 ↗
10. 10.1093/cid/ciy102510.1093/cid/ciy1025 ↗
11. 10.1200/JCO.2014.60.037910.1200/JCO.2014.60.0379 ↗
12. 10.1038/s41585-022-00602-410.1038/s41585-022-00602-4 ↗
13. 10.1016/j.matt.2023.09.00710.1016/j.matt.2023.09.007 ↗
14. 10.1039/D1MH01813B10.1039/D1MH01813B ↗
15. 10.1183/13993003.02244-201810.1183/13993003.02244-2018 ↗
16. 10.1126/sciadv.adg336510.1126/sciadv.adg3365 ↗
17. 10.1038/s41587-022-01244-y10.1038/s41587-022-01244-y ↗
18. 10.1111/imr.1226610.1111/imr.12266 ↗
19. 10.1016/j.actbio.2023.12.04510.1016/j.actbio.2023.12.045 ↗
20. 10.1002/adma.20210978910.1002/adma.202109789 ↗
21. 10.1021/acs.nanolett.7b0119310.1021/acs.nanolett.7b01193 ↗
22. 10.1016/j.biomaterials.2023.12213310.1016/j.biomaterials.2023.122133 ↗
23. 10.1002/anie.20170776910.1002/anie.201707769 ↗
24. 10.1002/adma.20230418710.1002/adma.202304187 ↗
25. 10.1038/nri324410.1038/nri3244 ↗
26. 10.1021/acsnano.3c0455610.1021/acsnano.3c04556 ↗
27. 10.1080/21655979.2022.203141510.1080/21655979.2022.2031415 ↗
28. 10.1126/sciadv.abi926510.1126/sciadv.abi9265 ↗
29. 10.1016/j.carbpol.2023.12066810.1016/j.carbpol.2023.120668 ↗
30. 10.1002/adma.20190295210.1002/adma.201902952 ↗
31. 10.1038/s41467-018-04390-710.1038/s41467-018-04390-7 ↗
32. 10.1021/acsnano.1c0670710.1021/acsnano.1c06707 ↗
33. 10.1038/s41467-020-14985-810.1038/s41467-020-14985-8 ↗
34. 10.1021/acsnano.0c0313110.1021/acsnano.0c03131 ↗
35. 10.1002/adma.20180829410.1002/adma.201808294 ↗
36. 10.1021/acsami.9b1755010.1021/acsami.9b17550 ↗
37. 10.1002/adma.20220698910.1002/adma.202206989 ↗
38. 10.1021/acsnano.1c0420610.1021/acsnano.1c04206 ↗
39. 10.1002/adfm.20230599210.1002/adfm.202305992 ↗
40. 10.1002/adhm.20190150210.1002/adhm.201901502 ↗
41. 10.1093/nsr/nwab06810.1093/nsr/nwab068 ↗
42. 10.1016/j.addr.2018.09.01010.1016/j.addr.2018.09.010 ↗
43. 10.1016/j.addr.2017.09.01810.1016/j.addr.2017.09.018 ↗
44. 10.1021/acsnano.3c0910710.1021/acsnano.3c09107 ↗
45. 10.1016/j.cell.2009.09.02810.1016/j.cell.2009.09.028 ↗
46. 10.1016/j.conb.2019.11.00610.1016/j.conb.2019.11.006 ↗
47. 10.1016/j.immuni.2020.06.02310.1016/j.immuni.2020.06.023 ↗
48. 10.1002/adma.20230477410.1002/adma.202304774 ↗
49. 10.1016/j.chom.2017.10.02010.1016/j.chom.2017.10.020 ↗
50. 10.1038/ni.263710.1038/ni.2637 ↗